Logo image of ICLR

ICON PLC (ICLR) Stock Fundamental Analysis

NASDAQ:ICLR - Nasdaq - IE0005711209 - Common Stock - Currency: USD

175.84  +0.48 (+0.27%)

After market: 175.84 0 (0%)

Fundamental Rating

5

Overall ICLR gets a fundamental rating of 5 out of 10. We evaluated ICLR against 54 industry peers in the Life Sciences Tools & Services industry. ICLR has only an average score on both its financial health and profitability. ICLR scores decently on growth, while it is valued quite cheap. This could make an interesting combination. With these ratings, ICLR could be worth investigating further for value investing!.


Dividend Valuation Growth Profitability Health

Quickly go to:

6

1. Profitability

1.1 Basic Checks

ICLR had positive earnings in the past year.
In the past year ICLR had a positive cash flow from operations.
In the past 5 years ICLR has always been profitable.
In the past 5 years ICLR always reported a positive cash flow from operatings.
ICLR Yearly Net Income VS EBIT VS OCF VS FCFICLR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

1.2 Ratios

ICLR has a Return On Assets of 4.78%. This is in the better half of the industry: ICLR outperforms 75.93% of its industry peers.
ICLR has a better Return On Equity (8.31%) than 77.78% of its industry peers.
With a decent Return On Invested Capital value of 6.57%, ICLR is doing good in the industry, outperforming 74.07% of the companies in the same industry.
Measured over the past 3 years, the Average Return On Invested Capital for ICLR is significantly below the industry average of 15.97%.
The last Return On Invested Capital (6.57%) for ICLR is above the 3 year average (5.80%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 4.78%
ROE 8.31%
ROIC 6.57%
ROA(3y)3.74%
ROA(5y)4.36%
ROE(3y)6.96%
ROE(5y)8.15%
ROIC(3y)5.8%
ROIC(5y)6.92%
ICLR Yearly ROA, ROE, ROICICLR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10 20 30

1.3 Margins

ICLR's Profit Margin of 9.82% is fine compared to the rest of the industry. ICLR outperforms 72.22% of its industry peers.
ICLR's Profit Margin has declined in the last couple of years.
ICLR has a better Operating Margin (14.43%) than 77.78% of its industry peers.
ICLR's Operating Margin has been stable in the last couple of years.
Looking at the Gross Margin, with a value of 28.65%, ICLR is doing worse than 75.93% of the companies in the same industry.
In the last couple of years the Gross Margin of ICLR has remained more or less at the same level.
Industry RankSector Rank
OM 14.43%
PM (TTM) 9.82%
GM 28.65%
OM growth 3Y9.91%
OM growth 5Y-0.95%
PM growth 3Y50.65%
PM growth 5Y-6.44%
GM growth 3Y2.3%
GM growth 5Y-0.09%
ICLR Yearly Profit, Operating, Gross MarginsICLR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10 20 30 40

More info and screens

5

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so ICLR is destroying value.
Compared to 1 year ago, ICLR has less shares outstanding
ICLR has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, ICLR has an improved debt to assets ratio.
ICLR Yearly Shares OutstandingICLR Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
ICLR Yearly Total Debt VS Total AssetsICLR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5B 10B 15B

2.2 Solvency

ICLR has an Altman-Z score of 2.15. This is not the best score and indicates that ICLR is in the grey zone with still only limited risk for bankruptcy at the moment.
ICLR has a Altman-Z score of 2.15. This is comparable to the rest of the industry: ICLR outperforms 55.56% of its industry peers.
The Debt to FCF ratio of ICLR is 3.45, which is a good value as it means it would take ICLR, 3.45 years of fcf income to pay off all of its debts.
ICLR has a Debt to FCF ratio of 3.45. This is in the better half of the industry: ICLR outperforms 74.07% of its industry peers.
ICLR has a Debt/Equity ratio of 0.35. This is a healthy value indicating a solid balance between debt and equity.
Looking at the Debt to Equity ratio, with a value of 0.35, ICLR is in line with its industry, outperforming 48.15% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.35
Debt/FCF 3.45
Altman-Z 2.15
ROIC/WACC0.85
WACC7.7%
ICLR Yearly LT Debt VS Equity VS FCFICLR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B 8B

2.3 Liquidity

A Current Ratio of 1.29 indicates that ICLR should not have too much problems paying its short term obligations.
ICLR has a Current ratio of 1.29. This is amonst the worse of the industry: ICLR underperforms 81.48% of its industry peers.
A Quick Ratio of 1.29 indicates that ICLR should not have too much problems paying its short term obligations.
With a Quick ratio value of 1.29, ICLR is not doing good in the industry: 70.37% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 1.29
Quick Ratio 1.29
ICLR Yearly Current Assets VS Current LiabilitesICLR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B

More info and screens

4

3. Growth

3.1 Past

ICLR shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -5.36%.
ICLR shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 15.23% yearly.
Looking at the last year, ICLR shows a decrease in Revenue. The Revenue has decreased by -2.91% in the last year.
ICLR shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 24.17% yearly.
EPS 1Y (TTM)-5.36%
EPS 3Y13.76%
EPS 5Y15.23%
EPS Q2Q%-13.07%
Revenue 1Y (TTM)-2.91%
Revenue growth 3Y14.75%
Revenue growth 5Y24.17%
Sales Q2Q%-4.85%

3.2 Future

ICLR is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 7.25% yearly.
The Revenue is expected to grow by 2.36% on average over the next years.
EPS Next Y-3.4%
EPS Next 2Y1.8%
EPS Next 3Y4.24%
EPS Next 5Y7.25%
Revenue Next Year-3.06%
Revenue Next 2Y-0.7%
Revenue Next 3Y1.14%
Revenue Next 5Y2.36%

3.3 Evolution

The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
ICLR Yearly Revenue VS EstimatesICLR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 2B 4B 6B 8B 10B
ICLR Yearly EPS VS EstimatesICLR Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 5 10 15 20 25

More info and screens

7

4. Valuation

4.1 Price/Earnings Ratio

Based on the Price/Earnings ratio of 13.29, the valuation of ICLR can be described as correct.
Based on the Price/Earnings ratio, ICLR is valued cheaper than 94.44% of the companies in the same industry.
ICLR's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 26.87.
The Price/Forward Earnings ratio is 12.12, which indicates a correct valuation of ICLR.
ICLR's Price/Forward Earnings ratio is rather cheap when compared to the industry. ICLR is cheaper than 92.59% of the companies in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 35.34, ICLR is valued rather cheaply.
Industry RankSector Rank
PE 13.29
Fwd PE 12.12
ICLR Price Earnings VS Forward Price EarningsICLR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40 50

4.2 Price Multiples

100.00% of the companies in the same industry are more expensive than ICLR, based on the Enterprise Value to EBITDA ratio.
94.44% of the companies in the same industry are more expensive than ICLR, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 13.82
EV/EBITDA 10.77
ICLR Per share dataICLR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 50 100

4.3 Compensation for Growth

The decent profitability rating of ICLR may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)0.87
EPS Next 2Y1.8%
EPS Next 3Y4.24%

More info and screens

0

5. Dividend

5.1 Amount

ICLR does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ICON PLC

NASDAQ:ICLR (8/15/2025, 8:00:02 PM)

After market: 175.84 0 (0%)

175.84

+0.48 (+0.27%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)07-23 2025-07-23/amc
Earnings (Next)10-21 2025-10-21/amc
Inst Owners96.39%
Inst Owner Change-3.02%
Ins Owners0.65%
Ins Owner ChangeN/A
Market Cap13.68B
Analysts80.8
Price Target221.61 (26.03%)
Short Float %2.82%
Short Ratio1.6
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-0.05%
Min EPS beat(2)-0.34%
Max EPS beat(2)0.23%
EPS beat(4)1
Avg EPS beat(4)-3.93%
Min EPS beat(4)-14.41%
Max EPS beat(4)0.23%
EPS beat(8)1
Avg EPS beat(8)-2.35%
EPS beat(12)3
Avg EPS beat(12)-1.69%
EPS beat(16)6
Avg EPS beat(16)-1.11%
Revenue beat(2)0
Avg Revenue beat(2)-1.42%
Min Revenue beat(2)-2.61%
Max Revenue beat(2)-0.23%
Revenue beat(4)0
Avg Revenue beat(4)-2.78%
Min Revenue beat(4)-6.75%
Max Revenue beat(4)-0.23%
Revenue beat(8)0
Avg Revenue beat(8)-2.61%
Revenue beat(12)0
Avg Revenue beat(12)-2.36%
Revenue beat(16)0
Avg Revenue beat(16)-2.13%
PT rev (1m)21.38%
PT rev (3m)14.09%
EPS NQ rev (1m)-0.71%
EPS NQ rev (3m)-6.54%
EPS NY rev (1m)0%
EPS NY rev (3m)-0.15%
Revenue NQ rev (1m)1.54%
Revenue NQ rev (3m)-4.4%
Revenue NY rev (1m)0.94%
Revenue NY rev (3m)0.8%
Valuation
Industry RankSector Rank
PE 13.29
Fwd PE 12.12
P/S 1.69
P/FCF 13.82
P/OCF 11.84
P/B 1.43
P/tB N/A
EV/EBITDA 10.77
EPS(TTM)13.23
EY7.52%
EPS(NY)14.51
Fwd EY8.25%
FCF(TTM)12.73
FCFY7.24%
OCF(TTM)14.86
OCFY8.45%
SpS104.02
BVpS122.86
TBVpS-38.32
PEG (NY)N/A
PEG (5Y)0.87
Profitability
Industry RankSector Rank
ROA 4.78%
ROE 8.31%
ROCE 8.31%
ROIC 6.57%
ROICexc 6.76%
ROICexgc 82.41%
OM 14.43%
PM (TTM) 9.82%
GM 28.65%
FCFM 12.23%
ROA(3y)3.74%
ROA(5y)4.36%
ROE(3y)6.96%
ROE(5y)8.15%
ROIC(3y)5.8%
ROIC(5y)6.92%
ROICexc(3y)5.97%
ROICexc(5y)8.67%
ROICexgc(3y)88.82%
ROICexgc(5y)90.84%
ROCE(3y)7.34%
ROCE(5y)8.76%
ROICexcg growth 3Y-4.45%
ROICexcg growth 5Y-5.01%
ROICexc growth 3Y27.99%
ROICexc growth 5Y-24.17%
OM growth 3Y9.91%
OM growth 5Y-0.95%
PM growth 3Y50.65%
PM growth 5Y-6.44%
GM growth 3Y2.3%
GM growth 5Y-0.09%
F-Score5
Asset Turnover0.49
Health
Industry RankSector Rank
Debt/Equity 0.35
Debt/FCF 3.45
Debt/EBITDA 2.18
Cap/Depr 43.25%
Cap/Sales 2.05%
Interest Coverage 250
Cash Conversion 74.49%
Profit Quality 124.6%
Current Ratio 1.29
Quick Ratio 1.29
Altman-Z 2.15
F-Score5
WACC7.7%
ROIC/WACC0.85
Cap/Depr(3y)27.79%
Cap/Depr(5y)38.09%
Cap/Sales(3y)1.87%
Cap/Sales(5y)1.83%
Profit Quality(3y)130.43%
Profit Quality(5y)205.36%
High Growth Momentum
Growth
EPS 1Y (TTM)-5.36%
EPS 3Y13.76%
EPS 5Y15.23%
EPS Q2Q%-13.07%
EPS Next Y-3.4%
EPS Next 2Y1.8%
EPS Next 3Y4.24%
EPS Next 5Y7.25%
Revenue 1Y (TTM)-2.91%
Revenue growth 3Y14.75%
Revenue growth 5Y24.17%
Sales Q2Q%-4.85%
Revenue Next Year-3.06%
Revenue Next 2Y-0.7%
Revenue Next 3Y1.14%
Revenue Next 5Y2.36%
EBIT growth 1Y3.81%
EBIT growth 3Y26.12%
EBIT growth 5Y22.99%
EBIT Next Year1.32%
EBIT Next 3Y3.51%
EBIT Next 5Y4.07%
FCF growth 1Y160.15%
FCF growth 3Y15.01%
FCF growth 5Y25.32%
OCF growth 1Y116.49%
OCF growth 3Y15.78%
OCF growth 5Y25.55%